In recent years, innovative drugs are driving the rapid expansion of China's pharmaceutical market
.
In the face of this change, multinational pharmaceutical companies have accelerated their pace and introduced more innovative drugs to China, while also accelerating localized innovation and cooperation
in China.
Recently, Xinhua Pharmaceutical and Bayer Healthcare Co.
, Ltd.
signed a Memorandum of Understanding on Strategic Cooperation, and the two parties intend to carry out in-depth strategic cooperation
in the field of health consumer goods.
The two sides are willing to jointly promote the construction of a new pattern of medicine and health care through cooperation such as dedication to new product research and development and in-depth expansion of e-commerce, in order to provide Chinese consumers with more and better pharmaceutical and health products and choices, and provide consumers with more accurate and personalized services
.
It is worth mentioning that since November 5, at the 5th China International Import Expo (hereinafter referred to as the "Expo"), the news of the "marriage" between multinational pharmaceutical companies and Chinese enterprises is also constantly coming, from drug research and development, to disease diagnosis, to drug promotion, etc.
, pharmaceutical companies are trying to build an ecological cooperation circle
.
For example, Johnson & Johnson announced that it will continue to increase investment in local R&D and innovation to create an open medical innovation ecosystem, and the company has also established a comprehensive cooperative relationship with Hangzhou Duoxi Biotechnology Co.
, Ltd.
to jointly develop new ADC drugs
.
In addition, Sanofi also announced that it and JD Health will once again upgrade their cooperation in the field of Internet medical care, and the two parties will expand the existing cooperation from the field of chronic diseases to the field of atopic dermatitis disease (AD), and meet the more diversified health needs
of patients with atopic dermatitis in the digital era by building the first one-stop AD online full-course management platform.
It can be seen from the above that multinational pharmaceutical companies are increasing their efforts to deepen local cooperation, including drug research and development, disease diagnosis, and drug promotion
.
In this regard, the industry believes that this is because the prospects of China's pharmaceutical market are attractive enough, causing multinational pharmaceutical companies to accelerate to seize the market
.
It is understood that thanks to China's policy dividends and industrial foundation, many multinational pharmaceutical companies are accelerating their localization development, and cooperation with domestic pharmaceutical companies is becoming more frequent
.
Taking AstraZeneca as an example, it has previously reached a strategic cooperation
with WuXi Biologics on the local production of pre-exposure prophylaxis neutralizing antibody drugs.
Voresa, jointly developed with Hutchison Pharmaceutical, achieved the world's first original drug incubated in China and was the first to be approved
in China.
In addition, AstraZeneca has also deepened its cooperation with local enterprise Luye Group and obtained the exclusive promotion right of its self-developed innovative proprietary Chinese medicine Blood Lipid Kang, helping its products go international
.
In general, China's pharmaceutical market has great potential and is ushering in a critical period
of rapid growth and high-quality development.
In this context, multinational pharmaceutical companies are expected to continue to deepen local cooperation, bringing all-round improvements
to China from products to management, technology, talent and quality standards.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
